Financings - Articles - Page 215

Financings for Feb. 12, 2024

Feb. 12, 2024

Biopharmas raising money in public or private financings, including: Lineage.

Med-tech financings 4Q23

With $17.68B raised, med-tech financings end 2023 with value down 54%

Med-tech financings 4Q23

Feb. 12, 2024

By Amanda Lanier

In 2023, med-tech firms garnered a total of $17.68 billion in funding, marking a 53.85% decline from the $38.31 billion raised in 2022 and ranking as the lowest financing year documented by BioWorld MedTech. This decrease follows a 22.3% dip from 2021’s $49.3 billion. The top-value year in med-tech financings remains 2020, recording $59.7 billion, followed by 2021’s $49.3 billion.

3D illustration of the cross-section of skin layers with atopic dermatitis

Dermatologic

Alys Pharmaceuticals launches with focus on immuno-dermatology pipeline

Feb. 12, 2024

Alys Pharmaceuticals Inc. has launched with a focus in the field of immuno-dermatology. Supported by $100 million in financing from Medicxi, Alys was formed through the aggregation of six asset-centric Medicxi companies: Aldena Therapeutics Inc., Graegis Pharmaceuticals Ltd., Granular Therapeutics Ltd., Klirna Biotech Sàrl, Nira Biosciences Inc. and Vimela Therapeutics Inc.

Metagenomi, Telomir price IPOs, test preclinical market appetite

Feb. 9, 2024

By Jennifer Boggs

Gene editing firm Metagenomi Inc. priced an IPO raising $93.8 million, while Telomir Pharmaceuticals Inc., a company developing small-molecule therapies targeting inflammatory disease, priced a more modest $7 million IPO. While they mark the second and third biopharma IPOs to price this week, and the sixth and seventh for 2024, the two aptly named companies are the first preclinical-stage ventures to test the public markets this year.

Financings for Feb. 9, 2024

Feb. 9, 2024

Biopharmas raising money in public or private financings, including: Alligator, Bioxcel, Cel-Sci, Evoke, Helix Acquisition, Immix, Lineage Cell, Sensorion, Tenax, Tenaya, TME, YM.

Elemind emerges from stealth with $12M for ‘electric medicine’ wearable

Feb. 9, 2024

By Annette Boyle

Elemind Technologies Inc. may not (yet) be telepathic, but the new company certainly read the mood of investors well as it secured $12 million in seed funding before emerging from stealth this week. While the product has yet to be fully revealed, the company is developing a wearable neurotechnology platform that uses artificial intelligence to read and guide brainwaves using tailored sound stimulation.

Med-tech deals January 2024

January launches med-tech firms with $100M in deals, $1.43B in M&As

Feb. 9, 2024

By Amanda Lanier

The new year kicked off with med-tech deal value in January totaling $107.75 million. By the numbers, January’s 183 deals surpassed the 2023 monthly average of approximately 142 deals per month.